company background image
6600

SciClone Pharmaceuticals (Holdings)SEHK:6600 Stock Report

Market Cap

HK$7.4b

7D

-6.2%

1Y

n/a

Updated

25 Sep, 2021

Data

Company Financials +
6600 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance3/6
Financial Health4/6
Dividends0/6

6600 Overview

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally.

SciClone Pharmaceuticals (Holdings) Competitors

China Resources Double-Crane PharmaceuticalLtd

SHSE:600062

CN¥12.5b

Sinopep-Allsino Bio PharmaceuticalLtd

SHSE:688076

CN¥11.5b

Harbin Pharmaceutical Group

SHSE:600664

CN¥8.7b

Hainan Shuangcheng Pharmaceuticals

SZSE:002693

CN¥1.9b

Price History & Performance

Summary of all time highs, changes and price drops for SciClone Pharmaceuticals (Holdings)
Historical stock prices
Current Share PriceHK$10.96
52 Week HighHK$9.31
52 Week LowHK$19.38
Beta0
1 Month Change14.29%
3 Month Change-25.75%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-41.70%

Recent News & Updates

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

The SciClone Pharmaceuticals (Holdings) Limited ( HKG:6600 ) share price has fared very poorly over the last month...

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Today we will run through one way of estimating the intrinsic value of SciClone Pharmaceuticals (Holdings) Limited...

Shareholder Returns

6600HK PharmaceuticalsHK Market
7D-6.2%-2.6%-2.4%
1Yn/a-12.0%9.1%

Return vs Industry: Insufficient data to determine how 6600 performed against the Hong Kong Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 6600 performed against the Hong Kong Market.

Price Volatility

Is 6600's price volatile compared to industry and market?
6600 volatility
6600 Beta0
Industry Beta0.59
Market Beta1

Stable Share Price: 6600 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 6600's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990850Hong Zhaohttps://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company’s proprietary product is Zadaxin, a thymalfasin for Injection. Its in-licensed products include Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome; and Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy.

SciClone Pharmaceuticals (Holdings) Fundamentals Summary

How do SciClone Pharmaceuticals (Holdings)'s earnings and revenue compare to its market cap?
6600 fundamental statistics
Market CapCN¥6.17b
Earnings (TTM)CN¥779.29m
Revenue (TTM)CN¥2.09b

7.9x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6600 income statement (TTM)
RevenueCN¥2.09b
Cost of RevenueCN¥478.30m
Gross ProfitCN¥1.61b
ExpensesCN¥831.31m
EarningsCN¥779.29m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.15
Gross Margin77.10%
Net Profit Margin37.31%
Debt/Equity Ratio80.2%

How did 6600 perform over the long term?

See historical performance and comparison

Valuation

Is SciClone Pharmaceuticals (Holdings) undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 6600 (HK$10.96) is trading below our estimate of fair value (HK$44.41)

Significantly Below Fair Value: 6600 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 6600 is good value based on its PE Ratio (7.9x) compared to the Hong Kong Pharmaceuticals industry average (9.8x).

PE vs Market: 6600 is good value based on its PE Ratio (7.9x) compared to the Hong Kong market (9.6x).


Price to Earnings Growth Ratio

PEG Ratio: 6600 is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: 6600 is overvalued based on its PB Ratio (3.2x) compared to the HK Pharmaceuticals industry average (1.1x).


Future Growth

How is SciClone Pharmaceuticals (Holdings) forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

3.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6600's forecast earnings growth (3.6% per year) is above the savings rate (1.5%).

Earnings vs Market: 6600's earnings (3.6% per year) are forecast to grow slower than the Hong Kong market (17.1% per year).

High Growth Earnings: 6600's earnings are forecast to grow, but not significantly.

Revenue vs Market: 6600's revenue (13.1% per year) is forecast to grow faster than the Hong Kong market (12.3% per year).

High Growth Revenue: 6600's revenue (13.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6600's Return on Equity is forecast to be high in 3 years time (27.7%)


Past Performance

How has SciClone Pharmaceuticals (Holdings) performed over the past 5 years?

28.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6600 has high quality earnings.

Growing Profit Margin: 6600's current net profit margins (37.3%) are lower than last year (39.4%).


Past Earnings Growth Analysis

Earnings Trend: 6600's earnings have grown significantly by 28.5% per year over the past 5 years.

Accelerating Growth: 6600's earnings growth over the past year (4%) is below its 5-year average (28.5% per year).

Earnings vs Industry: 6600 earnings growth over the past year (4%) underperformed the Pharmaceuticals industry 23.8%.


Return on Equity

High ROE: 6600's Return on Equity (40.4%) is considered outstanding.


Financial Health

How is SciClone Pharmaceuticals (Holdings)'s financial position?


Financial Position Analysis

Short Term Liabilities: 6600's short term assets (CN¥2.9B) exceed its short term liabilities (CN¥739.8M).

Long Term Liabilities: 6600's short term assets (CN¥2.9B) exceed its long term liabilities (CN¥1.2B).


Debt to Equity History and Analysis

Debt Level: 6600's debt to equity ratio (80.2%) is considered high.

Reducing Debt: Insufficient data to determine if 6600's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 6600's debt is well covered by operating cash flow (63.4%).

Interest Coverage: 6600's interest payments on its debt are well covered by EBIT (21.1x coverage).


Balance Sheet


Dividend

What is SciClone Pharmaceuticals (Holdings) current dividend yield, its reliability and sustainability?

1.97%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6600's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6600's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6600's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6600's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6600's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Hong Zhao (58 yo)

1.25yrs

Tenure

CN¥28,757,000

Compensation

Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...


CEO Compensation Analysis

Compensation vs Market: Hong's total compensation ($USD4.45M) is above average for companies of similar size in the Hong Kong market ($USD427.78K).

Compensation vs Earnings: Hong's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 6600's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: 6600's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: 6600 only recently listed within the past 12 months.


Top Shareholders

Company Information

SciClone Pharmaceuticals (Holdings) Limited's employee growth, exchange listings and data sources


Key Information

  • Name: SciClone Pharmaceuticals (Holdings) Limited
  • Ticker: 6600
  • Exchange: SEHK
  • Founded: 1990
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$7.430b
  • Shares outstanding: 677.87m
  • Website: https://www.sciclone.com

Number of Employees


Location

  • SciClone Pharmaceuticals (Holdings) Limited
  • Central Plaza
  • 22nd Floor
  • Shanghai
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 10:05
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.